User:Jweyenberg/BioZone Pharmaceuticals

BioZone Pharmaceuticals (OTC BB: BZNE) is a public pharmaceutical company that specializes in drug development, manufacturing, and marketing. The company has developed proprietary drug delivery technology that has enabled and revolutionized the administration of drugs that are difficult to formulate. The application of this technology allows the company to pursue reformulation of generic drugs and pursue a low-risk regulatory pathway for NDA approval. Additionally, BioZone provides oral, topical, and injectable drug products for anesthesia, infectious diseases, metabolic diseases, and oncology, and offers a unique line of dermatology products for a variety of dermatological diseases.

Early Years
Dr. Brian Keller, Ph.D. began what would eventually become BioZone Pharmaceuticals at his kitchen table in 1987 in Morin County, California. The first product Dr. Keller created was known as Enzone, an anti-inflamatory hemroidial cream. Enzone was also the first product offered by BioZone Laboratories.

BioZone Laboratories
Dr. Keller and Dan Fisher, who would be President of BioZone Labs, incorporated the company in 1989. At first developing and marketing their own products such as Enzone, the company also grew as a pharmaceutical contract manufacturer, manufacturing such products as Zicam, Dr. Brandt Detoxygen, and fatgirlslim products at the end of the company's operations as BioZone Laboratories. Also during this time, many proprietary technologies were created by the company. The most notable of these is the QuSome technology.

Side Projects
Offshoots of BioZone Laboratories included BetaZone, an international drug products development and licensing company that uses BioZone Pharmaceutical’s technology to formulate superior products.The company has developed a wide array of products and medications that treat conditions ranging from erectile dysfunction to dermatological issues, to pain and viruses. BetaZone’s products include Lysto® LipoSpray Sildenafil, DermaQ-mometasone, mupirocine, and clotrimazole. Other side projects include EquaChem and Equalan Pharmaceuticals. These companies served mainly to license the technologies of BioZone Laboratories and in some cases to market BioZone products under different names. All of these projects will be incorporated into BioZone Pharmaceuticals, either by integration or by becoming subsidiaries.

BioZone Pharmaceuticals
BioZone Pharmaceuticals went public in May 2011 and began the process of acquiring BioZone Laboratories and its subsidiaries. The IPO was facilitated by Marlin Capital with influence from pharmaceutical executive Phil Frost. BioZone Pharmaceuticals also acquired the full product line of Baker Cummins Dermatological. The mission of BioZone Pharmaceuticals is to become the leading provider of the highest quality pharmaceutical products in the industry. The company intends to accomplish this by continually pushing the limits of our talents, resources, and technology to provide exceptional medicine to the world. BioZone offers a full line of the highest quality dermatological products to treat psoriasis, seborrheic dermatitis, and dry skin of the entire body, including the scalp. Products offered by BioZone Pharmaceuticals include: P&S Liquid is an effective treatment for symptoms of psoriasis and seborrheic dermatitis that helps loosen and remove dry skin from the scalp.

P&S Shampoo is specially formulated to remove residual P&S Liquid from the hair. This product contains salicylic acid to control recurrent flaking and scaling of the scalp associated with seborrheic dermatitis and psoriasis. Ultra Mide 25 softens and moisturizes dry, rough, cracked, and calloused skin.

X-Seb Pearl is a therapeutic tar shampoo that relieves itching, irritation, redness, flaking, and scaling associated with dandruff, seborrheic dermatitis, and psoriasis of the scalp.

AquaDerm Cream is an ultra-rich facial moisturizer that softens, smoothes, and protects the skin. Aqua Derm is hypoallergenic, non-comedogenic, and non-greasy

GLYDERM® facials improve the texture and tone of the skin and clean out pores. The higher strengths of esterified glycolic acid reduce irritation, and are helpful and well-tolerated by patients who may be described as having considerable solar damage, thicker, or oilier skin.

Proprietary Technology
BioZone has createdQuSomes, a new liposome formulated by BioZone Pharmaceuticals. QuSomes are a lipid-based delivery system that is more cost effective than conventional technologies and substantially more versatile at satisfying the need for more effective skin care products. Compared to traditional liposomes, QuSomes perform better, cost less, and are manufactured in a cleaner, safer environment. Many BioZone products utilize the QuSome technology to facilitate faster, more efficient drug delivery, making these products one-of-a-kind in the drug market since the QuSome patent is owned by BioZone Pharmaceuticals. Biozone has also created a new, patented delivery system that represents a breakthrough in the lipid-based fill of soft gelatin and two-piece hard shell capsules and cosmetic delivery technology known collectively as Hypersorb technology. Hypersorb technology incorporates active ingredients into a self-emulsifying liquid complex that is then enrobed into a capsule for convenient oral administration. HyperSorb is especially suited for oral delivery of drugs with poor bioavailability. HyperSorb can also be used with drugs, proteins, hormones, and nutrients that cannot be absorbed from the GI tract, and are given by an invasive route of administration such as injection or nasal inhalation. Other proprietary technologies owned by BioZone Pharmaceuticals include Liquivail and EquaSomes.